Medication use in public pharmacies

KEY DATA SUMMARY

Analysis of the distribution and evolution of medication consumption in Belgium, in terms of volume and expenditure per insured (analysis and trends by region, province and district), for the year **2024**

NIHDI – Healthcare Service – Directorate Appropriate Care
Pascal Meeus, Lies Grypdonck, Benjamin Swine, Marc De Falleur, Katrien Declercq, Cindy Opdebeeck, Delphine Beauport
Contact: appropriatecare@riziv-inami.fgov.be

Date of report: 9 December 2025

CONTENTS

CONTENTS **2**

1. INTRODUCTION **4**

2. ALIMENTARY TRACT & METABOLISM **5**

Insulins and analogues 5

Proton pump inhibitors 6

Blood glucose lowering drugs except insulins 7

3. BLOOD & BLOOD FORMING ORGANS **8**

Antiaggregants 8

Oral anticoagulants 9

Heparin group 10

4. CARDIOVASCULAR SYSTEM **11**

Cardiovascular system drugs 11

Antiarrhythmics (class I & III) 12

Lipid-modifying agents 13

5. SYSTEMIC HORMONAL PREPARATIONS **14**

Levothyroxine (Thyroid hormone) 14

6. ANTIINFECTIVES FOR SYSTEMIC USE **15**

Antibiotics - All prescribers 15

Antibiotics (Amoxicillin) - All prescribers 16

Antibiotics - General medicine 17

Antibiotics - Paediatrics 18

Antibiotics - Gynaecology 19

Antibiotics - Internal medicine 20

Antibiotics - Gastroenterology 21

Antibiotics - Pneumology 22

Antibiotics - Surgery 23

Antibiotics - Urology 24

Antibiotics - Plastic surgery 25

Antibiotics - Dentistry 26

Antibiotics - Periodontology 27

7. MUSCULO-SKELETAL SYSTEM 28
Antigout preparations 28
Drugs affecting bone structure and mineralization 29
Non-steroidal anti-inflammatory drugs (NSAID) 30
8. NERVOUS SYSTEM 31
Antidepressants 31
Antipsychotics 32
Antivertigo preparations 33
Dopaminergic agents (anti-parkinson drug) 34
Gabapentinoids 35
Methylphenidate 36
Opioids 37
Antimigraine preparation 38
9. RESPIRATORY SYSTEM 39
Antihistamines for systemic use 39
Drugs for obstructive airway diseases 40
10. SENSORY ORGANS 41
Antiglaucoma preparations and miotics 41
11. IMMUNITY 42
Vaccination against influenza (65+/excl. nursing homes) 42
12. CROSS-SYSTEM ANALYSES 43
Polypharmacy (65 years and older) 43
Anticholinergics (65 years and older) 44
13. FOOTNOTES 45

1. INTRODUCTION

Since the 1st of October 2025, the Appropriate Care Unit has been integrated into the new Appropriate Care Directorate of the NIHDI's Healthcare Service.

It was on the initiative of the Appropriate Care Unit that analyses of the distribution and evolution of consumption, in terms of volume and expenditure per insured person in Belgium, were developed and refined over the years.

Its creation within the Research-Development-Quality Directorate of the NIHDI's Healthcare Service is a result of the NIHDI's 2016-2018 Administration Contract[1]. Article 35 of this contract refers to 'the setting up of an Appropriate Care Unit, aiming specifically to promote an integrated approach to the rational use of resources'. The Appropriate Care Unit has been up and running since the second quarter of 2017.

The tasks of the Unit were set out formally in the '2016-2017 Healthcare monitoring Action plan', published by NIHDI on 18 July 2016. This plan lists around thirty measures designed to make healthcare provision more efficient, by encouraging appropriate practice and tackling unnecessary or inappropriate care.

The plan states that one of the tasks of the Appropriate Care Unit is to analyse the 'appropriateness of care', in order to identify unexplained variations in consumption patterns, identified after standardisation. Such variations can potentially point to non-optimal use of resources.

"Medication use" documents report on the analyses carried out in this framework. Each report focuses on a particular topic.

In this document, we present the key data from each report relating to analyses of medication. Readers interested in the methodology used in these quantitative analyses should consult the document entitled 'Variations in consumption – Methodology'.

We have deliberately chosen not to attempt to interpret the figures, preferring to present the results to experts who are in a better position to do so. This document has nevertheless been made available to the public in order to provide objective, open input to discussions on this issue.

[1] (National Institute for Health and Disability Insurance, 2016)

2. ALIMENTARY TRACT & METABOLISM

Insulins and analogues

Main prescribers: *Endocrinology-diabetology*	44%	
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]	1,8%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	1,49%	
Median age	67 y.	
Percentage of women	45,5%	
Ratio Preferential rate/General rate	2,23	
Coefficient of variation (2024)	11,8%	
CONSUMPTION		
Annual consumption (DDD)	80.023.659	
Consumption of DDD (per 100.000 insured persons)	686.486	
Average annual consumption per insured consumer (in DDD)	459	
Percentage insured consumers with more than 3 times the average consumption	2,84%	
Coefficient of variation[2] (2014-2016)	13,81%	NS
Coefficient of variation[3] (2022-2024)	15,69%	
Trend[3] (2014-2024)	0,30%	NS
Trend[4] (2014-2022)	0,41%	**
Trend[5] (2022-2024)	-0,15%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	89.107.696€	
Average annual expenditure per insured	7,64€	
Average patient share per insured consumer	0,0%	
Percentage low-cost medication	32,1%	
Trend (2014-2024)	-0,41%	
Trend (2022-2024)	0,92%	

Link to the report: RAPPORT-EN-Antidiabetiques_-_Insulines_Et_Analogues_2024.pdf

Proton pump inhibitors

Main prescribers: *General practitioners*	80%	
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]	0,9%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	20,63%	
Median age	61 y.	
Percentage of women	57,9%	
Ratio Preferential rate/General rate	1,35	
Coefficient of variation (2024)	7,7%	
CONSUMPTION		
Annual consumption (DDD)	455.072.836	
Consumption of DDD (per 100.000 insured persons)	3.903.859	
Average annual consumption per insured consumer (in DDD)	189	
Percentage insured consumers with more than 3 times the average consumption	3,76%	
Coefficient of variation[2] (2014-2016)	13,94%	NS
Coefficient of variation[3] (2022-2024)	12,42%	
Trend[3] (2014-2024)	1,54%	**
Trend[4] (2014-2022)	1,79%	NS
Trend[5] (2022-2024)	0,52%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	113.124.313€	
Average annual expenditure per insured	9,7€	
Average patient share per insured consumer	21,9%	
Percentage low-cost medication	99,8%	
Trend (2014-2024)	0,84%	
Trend (2022-2024)	2,87%	

Link to the report: RAPPORT-EN-Inhibiteurs_De_La_Pompe_A_Protons_2024.pdf

Blood glucose lowering drugs except insulins

Main prescribers: *General practitioners*	76%	
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]	5,1%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	7,24%	
Median age	68 y.	
Percentage of women	47,5%	
Ratio Preferential rate/General rate	1,65	
Coefficient of variation (2024)	17,5%	
CONSUMPTION		
Annual consumption (DDD)	310.060.522	
Consumption of DDD (per 100.000 insured persons)	2.659.866	
Average annual consumption per insured consumer (in DDD)	367	
Percentage insured consumers with more than 3 times the average consumption	5,42%	
Coefficient of variation[2] (2014-2016)	16,27%	NS
Coefficient of variation[3] (2022-2024)	13,62%	
Trend[3] (2014-2024)	3,12%	***
Trend[4] (2014-2022)	2,31%	***
Trend[5] (2022-2024)	6,42%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	268.366.639€	
Average annual expenditure per insured	23,02€	
Average patient share per insured consumer	1,5%	
Percentage low-cost medication	64,8%	
Trend (2014-2024)	11,25%	
Trend (2022-2024)	16,57%	

Link to the report:
RAPPORT-EN-Antidiabetiques_-_Hypoglycemiants_A_Lexception_Des_Insulines_2024.pdf

3. BLOOD & BLOOD FORMING ORGANS

Antiaggregants

Main prescribers:	*General practitioners*	**78%**
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]		**5,3%**
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		**8,42%**
Median age		**72 y.**
Percentage of women		**45,9%**
Ratio Preferential rate/General rate		**1,35**
Coefficient of variation (2024)		**10,5%**
CONSUMPTION		
Annual consumption (DDD)		**352.187.708**
Consumption of DDD (per 100.000 insured persons)		**3.021.255**
Average annual consumption per insured consumer (in DDD)		**359**
Percentage insured consumers with more than 3 times the average consumption		**0,37%**
Coefficient of variation[2] (2014-2016)	**12,07%**	**NS**
Coefficient of variation[3] (2022-2024)	**12,61%**	
Trend[3] (2014-2024)	**-1,43%**	***
Trend[4] (2014-2022)	**-1,28%**	***
Trend[5] (2022-2024)	**-2,05%**	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		**27.506.283€**
Average annual expenditure per insured		**2,36€**
Average patient share per insured consumer		**14,6%**
Percentage low-cost medication		**11,2%**
Trend (2014-2024)		**-2,64%**
Trend (2022-2024)		**0,33%**

Link to the report: RAPPORT-EN-Antiagregants_2024.pdf

Oral anticoagulants

Main prescribers: *General practitioners*	**76%**	
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]	**2,3%**	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	**3,58%**	
Median age	**78 y.**	
Percentage of women	**46,3%**	
Ratio Preferential rate/General rate	**1,26**	
Coefficient of variation (2024)	**6,6%**	
CONSUMPTION		
Annual consumption (DDD)	**104.861.902**	
Consumption of DDD (per 100.000 insured persons)	**899.562**	
Average annual consumption per insured consumer (in DDD)	**251**	
Percentage insured consumers with more than 3 times the average consumption	**0,18%**	
Coefficient of variation[2] (2014-2016)	**17,15%**	**NS**
Coefficient of variation[3] (2022-2024)	**8,77%**	
Trend[3] (2014-2024)	**7,12%**	***
Trend[4] (2014-2022)	**8,16%**	***
Trend[5] (2022-2024)	**3,10%**	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	**256.721.944€**	
Average annual expenditure per insured	**22,02€**	
Average patient share per insured consumer	**6,5%**	
Percentage low-cost medication	**12,5%**	
Trend (2014-2024)	**11,90%**	
Trend (2022-2024)	**0,51%**	

Link to the report: RAPPORT-EN-Anticoagulants_Oraux_2024.pdf

Heparin group

Main prescribers: *General practitioners*	39%	
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]	1,5%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	2,76%	
Median age	59 y.	
Percentage of women	60,3%	
Ratio Preferential rate/General rate	1,23	
Coefficient of variation (2024)	18,7%	
CONSUMPTION		
Annual consumption (DDD)	19.052.928	
Consumption of DDD (per 100.000 insured persons)	163.446	
Average annual consumption per insured consumer (in DDD)	59	
Percentage insured consumers with more than 3 times the average consumption	4,97%	
Coefficient of variation[2] (2014-2016)	25,56%	NS
Coefficient of variation[3] (2022-2024)	30,03%	
Trend[3] (2014-2024)	-5,74%	***
Trend[4] (2014-2022)	-5,24%	***
Trend[5] (2022-2024)	-7,71%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	31.219.445€	
Average annual expenditure per insured	2,68€	
Average patient share per insured consumer	20,3%	
Percentage low-cost medication	8,2%	
Trend (2014-2024)	-5,17%	
Trend (2022-2024)	-2,51%	

Link to the report: RAPPORT-EN-Groupe_Des_Heparines_2024.pdf

4. CARDIOVASCULAR SYSTEM

Cardiovascular system drugs

Main prescribers: *General practitioners*	82%	
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]	3,6%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	29,25%	
Median age	67 y.	
Percentage of women	52,2%	
Ratio Preferential rate/General rate	1,14	
Coefficient of variation (2024)	5,5%	
CONSUMPTION		
Annual consumption (DDD)	2.161.167.839	
Consumption of DDD (per 100.000 insured persons)	18.539.659	
Average annual consumption per insured consumer (in DDD)	634	
Percentage insured consumers with more than 3 times the average consumption	3,70%	
Coefficient of variation[2] (2014-2016)	8,64%	NS
Coefficient of variation[3] (2022-2024)	7,39%	
Trend[3] (2014-2024)	-0,34%	***
Trend[4] (2014-2022)	-0,74%	***
Trend[5] (2022-2024)	1,29%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	539.929.055€	
Average annual expenditure per insured	46,32€	
Average patient share per insured consumer	17,8%	
Percentage low-cost medication	88,6%	
Trend (2014-2024)	-0,42%	
Trend (2022-2024)	14,79%	

Link to the report: RAPPORT-EN-Medication_Du_Systeme_Cardio-vasculaire_2024.pdf

Antiarrhythmics (class I & III)

Main prescribers: *General practitioners*	75%	
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]	2,7%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	1,22%	
Median age	76 y.	
Percentage of women	49,8%	
Ratio Preferential rate/General rate	1,11	
Coefficient of variation (2024)	26,5%	
CONSUMPTION		
Annual consumption (DDD)	32.020.343	
Consumption of DDD (per 100.000 insured persons)	274.688	
Average annual consumption per insured consumer (in DDD)	225	
Percentage insured consumers with more than 3 times the average consumption	0,40%	
Coefficient of variation[2] (2014-2016)	32,69%	NS
Coefficient of variation[3] (2022-2024)	29,51%	
Trend[3] (2014-2024)	-1,62%	***
Trend[4] (2014-2022)	-1,57%	NS
Trend[5] (2022-2024)	-1,83%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	10.483.155€	
Average annual expenditure per insured	0,9€	
Average patient share per insured consumer	22,3%	
Percentage low-cost medication	54,7%	
Trend (2014-2024)	-0,23%	
Trend (2022-2024)	1,26%	

Link to the report: RAPPORT-EN-Medicat_Cardio-vasc_Antiarythmiques_Classe_I_Et_Iii_2024.pdf

Lipid-modifying agents

Main prescribers: *General practitioners*	81%	
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI)[1]	2,0%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	18,35%	
Median age	68 y.	
Percentage of women	47,9%	
Ratio Preferential rate/General rate	1,13	
Coefficient of variation (2024)	9,4%	
CONSUMPTION		
Annual consumption (DDD)	819.785.508	
Consumption of DDD (per 100.000 insured persons)	7.032.561	
Average annual consumption per insured consumer (in DDD)	383	
Percentage insured consumers with more than 3 times the average consumption	3,68%	
Coefficient of variation[2] (2014-2016)	11,95%	NS
Coefficient of variation[3] (2022-2024)	12,79%	
Trend[3] (2014-2024)	3,17%	***
Trend[4] (2014-2022)	2,37%	***
Trend[5] (2022-2024)	6,39%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	247.719.578€	
Average annual expenditure per insured	21,25€	
Average patient share per insured consumer	15,9%	
Percentage low-cost medication	97,3%	
Trend (2014-2024)	2,30%	
Trend (2022-2024)	33,01%	

Link to the report: RAPPORT-EN-Medicat_Cardio-vasc_-_Hypolipidemiants_2024.pdf

5. SYSTEMIC HORMONAL PREPARATIONS

Levothyroxine (Thyroid hormone)

Main prescribers: *General practitioners*	75%	
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]	0,2%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	5,88%	
Median age	63 y.	
Percentage of women	81,7%	
Ratio Preferential rate/General rate	1,21	
Coefficient of variation (2024)	41,7%	
CONSUMPTION		
Annual consumption (DDD)	131.736.116	
Consumption of DDD (per 100.000 insured persons)	1.130.103	
Average annual consumption per insured consumer (in DDD)	192	
Percentage insured consumers with more than 3 times the average consumption	1,11%	
Coefficient of variation[2] (2014-2016)	45,53%	NS
Coefficient of variation[3] (2022-2024)	40,45%	
Trend[3] (2014-2024)	0,25%	NS
Trend[4] (2014-2022)	0,09%	*
Trend[5] (2022-2024)	0,93%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	18.174.938€	
Average annual expenditure per insured	1,56€	
Average patient share per insured consumer	13,3%	
Percentage low-cost medication	NA	
Trend (2014-2024)	2,23%	
Trend (2022-2024)	7,27%	

Link to the report: RAPPORT-EN-Levothyroxine_Hormone_Thyroidienne_2024.pdf

6. ANTIINFECTIVES FOR SYSTEMIC USE

Antibiotics - All prescribers

Main prescribers:	*General practitioners*	**66%**
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]		**10,1%**
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		**34,20%**
Median age		**46 y.**
Percentage of women		**57,2%**
Ratio Preferential rate/General rate		**1,11**
Coefficient of variation (2024)		**12,2%**
CONSUMPTION		
Annual consumption (DDD)		**81.469.357**
Consumption of DDD (per 100.000 insured persons)		**698.888**
Average annual consumption per insured consumer (in DDD)		**20**
Percentage insured consumers with more than 3 times the average consumption		**4,06%**
Coefficient of variation[2] (2014-2016)	**8,76%**	**NS**
Coefficient of variation[3] (2022-2024)	**10,83%**	
Trend[3] (2014-2024)	**-1,93%**	***
Trend[4] (2014-2022)	**-3,01%**	***
Trend[5] (2022-2024)	**2,51%**	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		**67.246.472€**
Average annual expenditure per insured		**5,77€**
Average patient share per insured consumer		**37,0%**
Percentage low-cost medication		**81,1%**
Trend (2014-2024)		**-5,22%**
Trend (2022-2024)		**6,70%**

Link to the report: RAPPORT-EN-Antibiotiques_Tous_Prescripteurs_2024.pdf

Antibiotics (Amoxicillin) - All prescribers

Main prescribers: *General practitioners*	**64%**	
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]	**4,6%**	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	**20,94%**	
Median age	**43 y.**	
Percentage of women	**53,2%**	
Ratio Preferential rate/General rate	**1,19**	
Coefficient of variation (2024)	**12,3%**	
CONSUMPTION		
Annual consumption (DDD)	**37.958.747**	
Consumption of DDD (per 100.000 insured persons)	**325.631**	
Average annual consumption per insured consumer (in DDD)	**16**	
Percentage insured consumers with more than 3 times the average consumption	**1,99%**	
Coefficient of variation[2] (2014-2016)	**9,48%**	**NS**
Coefficient of variation[3] (2022-2024)	**13,58%**	
Trend[3] (2014-2024)	**-1,54%**	***
Trend[4] (2014-2022)	**-2,22%**	***
Trend[5] (2022-2024)	**1,24%**	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	**28.325.871€**	
Average annual expenditure per insured	**2,43€**	
Average patient share per insured consumer	**37,5%**	
Percentage low-cost medication	**100,0%**	
Trend (2014-2024)	**-4,41%**	
Trend (2022-2024)	**4,49%**	

Link to the report: RAPPORT-EN-Antibiotiques_Amoxicilline_Tous_Prescripteurs_2024.pdf

Antibiotics - General medicine

Main prescribers:	*10004 - Accredited general practitioner + ECG*	74%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI)[1]		10,1%
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		26,84%
Median age		47 y.
Percentage of women		58,7%
Ratio Preferential rate/General rate		1,11
Coefficient of variation (2024)		15,3%
CONSUMPTION		
Annual consumption (DDD)		58.540.951
Consumption of DDD (per 100.000 insured persons)		502.196
Average annual consumption per insured consumer (in DDD)		19
Percentage insured consumers with more than 3 times the average consumption		3,65%
Coefficient of variation[2] (2014-2016)		12,09%
Coefficient of variation[3] (2022-2024)		14,28%
Trend[3] (2014-2024)		-2,46%
Trend[4] (2014-2022)		-3,51%
Trend[5] (2022-2024)		1,83%
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		45.891.456€
Average annual expenditure per insured		3,94€
Average patient share per insured consumer		38,1%
Percentage low-cost medication		81,0%
Trend (2014-2024)		-5,76%
Trend (2022-2024)		7,10%

NS	
***	
***	

Link to the report: RAPPORT-EN-Antibiotiques_Medecine_Generale_2024.pdf

Antibiotics - Paediatrics

Main prescribers:	*10690 - Specialist in paediatrics*	**80%**
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]		**10,1%**
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		**1,41%**
Median age		**4 y.**
Percentage of women		**49,4%**
Ratio Preferential rate/General rate		**0,8**
Coefficient of variation (2024)		**26,7%**
CONSUMPTION		
Annual consumption (DDD)		**1.744.190**
Consumption of DDD (per 100.000 insured persons)		**14.963**
Average annual consumption per insured consumer (in DDD)		**11**
Percentage insured consumers with more than 3 times the average consumption		**3,90%**
Coefficient of variation[2] (2014-2016)		**22,34%**
Coefficient of variation[3] (2022-2024)		**28%**
Trend[3] (2014-2024)		**0,07%**
Trend[4] (2014-2022)		**-1,40%**
Trend[5] (2022-2024)		**6,17%**
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		**3.030.115€**
Average annual expenditure per insured		**0,26€**
Average patient share per insured consumer		**23,1%**
Percentage low-cost medication		**95,2%**
Trend (2014-2024)		**-6,33%**
Trend (2022-2024)		**2,43%**

NS
*
***

Link to the report: [RAPPORT-EN-Antibiotiques_Pediatrie_2024.pdf]

Antibiotics - Gynaecology

Main prescribers:	*10340 - Specialist in gynaecology-obstetrics*	82%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]		10,1%
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		0,67%
Median age		36 y.
Percentage of women		97,0%
Ratio Preferential rate/General rate		1,12
Coefficient of variation (2024)		25,1%
CONSUMPTION		
Annual consumption (DDD)		906.971
Consumption of DDD (per 100.000 insured persons)		7.780
Average annual consumption per insured consumer (in DDD)		12
Percentage insured consumers with more than 3 times the average consumption		3,83%
Coefficient of variation[2] (2014-2016)		24,6%
Coefficient of variation[3] (2022-2024)		23,49%
Trend[3] (2014-2024)		-1,62%
Trend[4] (2014-2022)		-2,23%
Trend[5] (2022-2024)		0,85%
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		851.485€
Average annual expenditure per insured		0,07€
Average patient share per insured consumer		34,7%
Percentage low-cost medication		64,2%
Trend (2014-2024)		-3,84%
Trend (2022-2024)		5,44%

NS	
***	
***	

Link to the report: RAPPORT-EN-Antibiotiques_Gynecologie_2024.pdf

Antibiotics - Internal medicine

Main prescribers:	*10580 - Specialist in internal medicine*	88%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]		10,1%
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		0,18%
Median age		50 y.
Percentage of women		50,7%
Ratio Preferential rate/General rate		1,56
Coefficient of variation (2024)		68,5%
CONSUMPTION		
Annual consumption (DDD)		540.414
Consumption of DDD (per 100.000 insured persons)		4.636
Average annual consumption per insured consumer (in DDD)		26
Percentage insured consumers with more than 3 times the average consumption		6,60%
Coefficient of variation[2] (2014-2016)		35,9%
Coefficient of variation[3] (2022-2024)		59,69%
Trend[3] (2014-2024)		-4,20%
Trend[4] (2014-2022)		-6,66%
Trend[5] (2022-2024)		6,33%
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		542.749€
Average annual expenditure per insured		0,05€
Average patient share per insured consumer		29,5%
Percentage low-cost medication		91,6%
Trend (2014-2024)		-8,38%
Trend (2022-2024)		5,48%

NS
***
**

Link to the report: RAPPORT-EN-Antibiotiques_Medecine_Interne_2024.pdf

Antibiotics - Gastroenterology

Main prescribers:	*10650 - Specialist in gastroentero-logy*	65%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]		10,1%
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		0,20%
Median age		56 y.
Percentage of women		53,6%
Ratio Preferential rate/General rate		1,52
Coefficient of variation (2024)		28,1%
CONSUMPTION		
Annual consumption (DDD)		575.624
Consumption of DDD (per 100.000 insured persons)		4.938
Average annual consumption per insured consumer (in DDD)		25
Percentage insured consumers with more than 3 times the average consumption		2,07%
Coefficient of variation[2] (2014-2016)		33,09%
Coefficient of variation[3] (2022-2024)		33,96%
Trend[3] (2014-2024)		-1,63%
Trend[4] (2014-2022)		-2,90%
Trend[5] (2022-2024)		3,63%
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		394.951€
Average annual expenditure per insured		0,03€
Average patient share per insured consumer		40,6%
Percentage low-cost medication		92,1%
Trend (2014-2024)		-5,36%
Trend (2022-2024)		8,62%

Link to the report: RAPPORT-EN-Antibiotiques_Gastroenterologie_2024.pdf

Antibiotics - Pneumology

Main prescribers:	*10620 - Specialist in pneumology*	**60%**
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]		**10,1%**
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		**0,36%**
Median age		**65 y.**
Percentage of women		**52,4%**
Ratio Preferential rate/General rate		**1,76**
Coefficient of variation (2024)		**22,7%**
CONSUMPTION		
Annual consumption (DDD)		**1.520.139**
Consumption of DDD (per 100.000 insured persons)		**13.041**
Average annual consumption per insured consumer (in DDD)		**36**
Percentage insured consumers with more than 3 times the average consumption		**7,62%**
Coefficient of variation[2] (2014-2016)	**30,65%**	**NS**
Coefficient of variation[3] (2022-2024)	**33,37%**	
Trend[3] (2014-2024)	**4,31%**	***
Trend[4] (2014-2022)	**2,63%**	*
Trend[5] (2022-2024)	**11,32%**	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		**2.129.810€**
Average annual expenditure per insured		**0,18€**
Average patient share per insured consumer		**24,0%**
Percentage low-cost medication		**89,8%**
Trend (2014-2024)		**-1,03%**
Trend (2022-2024)		**-2,88%**

Link to the report: RAPPORT-EN-Antibiotiques_Pneumologie_2024.pdf

Antibiotics - Surgery

Main prescribers:	*10140 - Specialist in surgery*	**87%**
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]		**10,1%**
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		**0,28%**
Median age		**52 y.**
Percentage of women		**47,9%**
Ratio Preferential rate/General rate		**1,39**
Coefficient of variation (2024)		**29,6%**
CONSUMPTION		
Annual consumption (DDD)		**528.483**
Consumption of DDD (per 100.000 insured persons)		**4.534**
Average annual consumption per insured consumer (in DDD)		**16**
Percentage insured consumers with more than 3 times the average consumption		**3,68%**
Coefficient of variation [2] (2014-2016)		**38,29%**
Coefficient of variation [3] (2022-2024)		**27,97%**
Trend [3] (2014-2024)		**-2,52%**
Trend [4] (2014-2022)		**-4,38%**
Trend [5] (2022-2024)		**5,32%**
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		**441.885€**
Average annual expenditure per insured		**0,04€**
Average patient share per insured consumer		**40,7%**
Percentage low-cost medication		**93,5%**
Trend (2014-2024)		**-5,80%**
Trend (2022-2024)		**10,17%**

NS
***
***

Link to the report: [RAPPORT-EN-Antibiotiques_Chirurgie_2024.pdf]

Antibiotics - Urology

Main prescribers: *10450 - Specialist in urology*	79%	
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]	10,1%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	0,60%	
Median age	67 y.	
Percentage of women	40,5%	
Ratio Preferential rate/General rate	1,23	
Coefficient of variation (2024)	22,2%	
CONSUMPTION		
Annual consumption (DDD)	1.159.150	
Consumption of DDD (per 100.000 insured persons)	9.944	
Average annual consumption per insured consumer (in DDD)	17	
Percentage insured consumers with more than 3 times the average consumption	4,79%	
Coefficient of variation[2] (2014-2016)	26,7%	NS
Coefficient of variation[3] (2022-2024)	30,89%	
Trend[3] (2014-2024)	-5,62%	***
Trend[4] (2014-2022)	-6,60%	***
Trend[5] (2022-2024)	-1,60%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	1.095.899€	
Average annual expenditure per insured	0,09€	
Average patient share per insured consumer	34,8%	
Percentage low-cost medication	52,9%	
Trend (2014-2024)	-5,24%	
Trend (2022-2024)	6,28%	

Link to the report: RAPPORT-EN-Antibiotiques_Urologie_2024.pdf

Antibiotics - Plastic surgery

Main prescribers: *10210 - Specialist in plastic surgery*	**74%**	
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]	**10,1%**	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	**0,14%**	
Median age	**49 y.**	
Percentage of women	**76,5%**	
Ratio Preferential rate/General rate	**0,91**	
Coefficient of variation (2024)	**27,0%**	
CONSUMPTION		
Annual consumption (DDD)	**206.834**	
Consumption of DDD (per 100.000 insured persons)	**1.774**	
Average annual consumption per insured consumer (in DDD)	**13**	
Percentage insured consumers with more than 3 times the average consumption	**2,36%**	
Coefficient of variation[2] (2014-2016)	**36,87%**	**NS**
Coefficient of variation[3] (2022-2024)	**23,74%**	
Trend[3] (2014-2024)	**1,33%**	**NS**
Trend[4] (2014-2022)	**-0,07%**	***
Trend[5] (2022-2024)	**7,13%**	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	**177.524€**	
Average annual expenditure per insured	**0,02€**	
Average patient share per insured consumer	**40,2%**	
Percentage low-cost medication	**93,1%**	
Trend (2014-2024)	**-2,26%**	
Trend (2022-2024)	**11,00%**	

Link to the report: RAPPORT-EN-Antibiotiques_Chirurgie_Plastique_2024.pdf

Antibiotics - Dentistry

Main prescribers:	*30001 - Dental science graduates - general dentist*	**94%**
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]		**10,1%**
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		**3,86%**
Median age		**50 y.**
Percentage of women		**52,4%**
Ratio Preferential rate/General rate		**1,39**
Coefficient of variation (2024)		**28,2%**
CONSUMPTION		
Annual consumption (DDD)		**5.075.956**
Consumption of DDD (per 100.000 insured persons)		**43.544**
Average annual consumption per insured consumer (in DDD)		**11**
Percentage insured consumers with more than 3 times the average consumption		**1,89%**
Coefficient of variation[2] (2014-2016)		**21,31%**
Coefficient of variation[3] (2022-2024)		**28,87%** — **NS**
Trend[3] (2014-2024)		**0,70%** — **NS**
Trend[4] (2014-2022)		**0,27%**
Trend[5] (2022-2024)		**2,44%** — ***
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		**4.294.032€**
Average annual expenditure per insured		**0,37€**
Average patient share per insured consumer		**36,1%**
Percentage low-cost medication		**99,4%**
Trend (2014-2024)		**-3,34%**
Trend (2022-2024)		**5,45%**

Link to the report: RAPPORT-EN-Antibiotiques_Dentistes_2024.pdf

Antibiotics - Periodontology

Main prescribers:	*30006 - Dentists specialised in perio-dontology*	**95%**
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]		**10,1%**
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		**0,25%**
Median age		**57 y.**
Percentage of women		**56,0%**
Ratio Preferential rate/General rate		**0,39**
Coefficient of variation (2024)		**40,9%**
CONSUMPTION		
Annual consumption (DDD)		**271.637**
Consumption of DDD (per 100.000 insured persons)		**2.330**
Average annual consumption per insured consumer (in DDD)		**9**
Percentage insured consumers with more than 3 times the average consumption		**1,44%**
Coefficient of variation[2] (2014-2016)		**46,1%**
Coefficient of variation[3] (2022-2024)		**45,33%** **NS**
Trend[3] (2014-2024)		**8,28%** ***
Trend[4] (2014-2022)		**8,99%**
Trend[5] (2022-2024)		**5,48%** **NS**
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		**238.678€**
Average annual expenditure per insured		**0,02€**
Average patient share per insured consumer		**33,4%**
Percentage low-cost medication		**99,8%**
Trend (2014-2024)		**4,31%**
Trend (2022-2024)		**8,61%**

Link to the report: RAPPORT-EN-Antibiotiques_Parodontologues_2024.pdf

7. MUSCULO-SKELETAL SYSTEM

Antigout preparations

Main prescribers: *General practitioners*	83%	
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]	1,3%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	2,93%	
Median age	70 y.	
Percentage of women	25,3%	
Ratio Preferential rate/General rate	1,1	
Coefficient of variation (2024)	17,8%	
CONSUMPTION		
Annual consumption (DDD)	53.413.891	
Consumption of DDD (per 100.000 insured persons)	458.213	
Average annual consumption per insured consumer (in DDD)	156	
Percentage insured consumers with more than 3 times the average consumption	1,25%	
Coefficient of variation[2] (2014-2016)	17,61%	NS
Coefficient of variation[3] (2022-2024)	17,02%	
Trend[3] (2014-2024)	1,23%	***
Trend[4] (2014-2022)	1,80%	***
Trend[5] (2022-2024)	-1,02%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	10.039.034€	
Average annual expenditure per insured	0,86€	
Average patient share per insured consumer	15,1%	
Percentage low-cost medication	91,5%	
Trend (2014-2024)	1,71%	
Trend (2022-2024)	3,38%	

Link to the report: RAPPORT-EN-Antigoutteux_2024.pdf

Drugs affecting bone structure and mineralization

Main prescribers: *General practitioners*	63%	
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]	1,8%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	1,33%	
Median age	74 y.	
Percentage of women	87,3%	
Ratio Preferential rate/General rate	1,18	
Coefficient of variation (2024)	26,4%	
CONSUMPTION		
Annual consumption (DDD)	60.972.943	
Consumption of DDD (per 100.000 insured persons)	523.059	
Average annual consumption per insured consumer (in DDD)	394	
Percentage insured consumers with more than 3 times the average consumption	3,94%	
Coefficient of variation[2] (2014-2016)	15,51%	NS
Coefficient of variation[3] (2022-2024)	27,15%	
Trend[3] (2014-2024)	-0,94%	**
Trend[4] (2014-2022)	-1,62%	***
Trend[5] (2022-2024)	1,82%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	51.094.592€	
Average annual expenditure per insured	4,38€	
Average patient share per insured consumer	5,7%	
Percentage low-cost medication	32,1%	
Trend (2014-2024)	-0,37%	
Trend (2022-2024)	10,59%	

Link to the report:
RAPPORT-EN-Preparations_Affectant_La_Structure_Et_La_Mineralisation_De_Los_2024.pdf

Non-steroidal anti-inflammatory drugs (NSAID)

Main prescribers: *General practitioners*	**72%**	
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]	**33,6%**	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	**23,45%**	
Median age	**50 y.**	
Percentage of women	**54,9%**	
Ratio Preferential rate/General rate	**1,07**	
Coefficient of variation (2024)	**11,2%**	
CONSUMPTION		
Annual consumption (DDD)	**128.443.750**	
Consumption of DDD (per 100.000 insured persons)	**1.101.859**	
Average annual consumption per insured consumer (in DDD)	**47**	
Percentage insured consumers with more than 3 times the average consumption	**4,84%**	
Coefficient of variation[2] (2014-2016)	**10,65%**	**NS**
Coefficient of variation[3] (2022-2024)	**17,62%**	
Trend[3] (2014-2024)	**-2,32%**	***
Trend[4] (2014-2022)	**-2,67%**	***
Trend[5] (2022-2024)	**-0,90%**	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	**39.238.350€**	
Average annual expenditure per insured	**3,37€**	
Average patient share per insured consumer	**12,8%**	
Percentage low-cost medication	**89,9%**	
Trend (2014-2024)	**-3,39%**	
Trend (2022-2024)	**3,10%**	

Link to the report: RAPPORT-EN-Anti-inflammatoires_Non_Steroidiens_Ains_2024.pdf

8. NERVOUS SYSTEM

Antidepressants

Main prescribers:	*General practitioners*	74%
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]		1,0%
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers		11,68%
Median age		58 y.
Percentage of women		65,7%
Ratio Preferential rate/General rate		1,72
Coefficient of variation (2024)		11,2%
CONSUMPTION		
Annual consumption (DDD)		396.983.167
Consumption of DDD (per 100.000 insured persons)		3.405.535
Average annual consumption per insured consumer (in DDD)		292
Percentage insured consumers with more than 3 times the average consumption		4,04%
Coefficient of variation[2] (2014-2016)		16,42% NS
Coefficient of variation[3] (2022-2024)		13,02%
Trend[3] (2014-2024)		1,81% ***
Trend[4] (2014-2022)		1,73% *
Trend[5] (2022-2024)		2,13%
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance		93.676.744€
Average annual expenditure per insured		8,04€
Average patient share per insured consumer		21,0%
Percentage low-cost medication		95,9%
Trend (2014-2024)		-3,84%
Trend (2022-2024)		4,05%

Link to the report: RAPPORT-EN-Antidepresseurs_2024.pdf

Antipsychotics

Main prescribers: *General practitioners*	57%	
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]	1,9%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	3,25%	
Median age	57 y.	
Percentage of women	54,6%	
Ratio Preferential rate/General rate	3,68	
Coefficient of variation (2024)	13,4%	
CONSUMPTION		
Annual consumption (DDD)	57.700.697	
Consumption of DDD (per 100.000 insured persons)	494.988	
Average annual consumption per insured consumer (in DDD)	152	
Percentage insured consumers with more than 3 times the average consumption	8,13%	
Coefficient of variation[2] (2014-2016)	15,02%	NS
Coefficient of variation[3] (2022-2024)	15,2%	
Trend[3] (2014-2024)	0,03%	NS
Trend[4] (2014-2022)	0,45%	***
Trend[5] (2022-2024)	-1,62%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	78.899.926€	
Average annual expenditure per insured	6,77€	
Average patient share per insured consumer	12,0%	
Percentage low-cost medication	78,5%	
Trend (2014-2024)	-4,22%	
Trend (2022-2024)	-3,83%	

Link to the report: RAPPORT-EN-Antipsychotiques_2024.pdf

Antivertigo preparations

Main prescribers: *General practitioners*	84%	
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]	8,8%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	1,48%	
Median age	70 y.	
Percentage of women	69,7%	
Ratio Preferential rate/General rate	1,39	
Coefficient of variation (2024)	21,7%	
CONSUMPTION		
Annual consumption (DDD)	35.302.852	
Consumption of DDD (per 100.000 insured persons)	302.847	
Average annual consumption per insured consumer (in DDD)	205	
Percentage insured consumers with more than 3 times the average consumption	7,32%	
Coefficient of variation[2] (2014-2016)	28,34%	NS
Coefficient of variation[3] (2022-2024)	30,33%	
Trend[3] (2014-2024)	-1,59%	***
Trend[4] (2014-2022)	-0,97%	***
Trend[5] (2022-2024)	-4,04%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	2.886.232€	
Average annual expenditure per insured	0,25€	
Average patient share per insured consumer	61,2%	
Percentage low-cost medication	41,7%	
Trend (2014-2024)	-0,27%	
Trend (2022-2024)	9,76%	

Link to the report: RAPPORT-EN-Preparations_Antivertigineuses_2024.pdf

Dopaminergic agents (anti-parkinson drug)

Main prescribers: *General practitioners*	**59%**	
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]	**3,2%**	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	**0,71%**	
Median age	**75 y.**	
Percentage of women	**54,8%**	
Ratio Preferential rate/General rate	**1,49**	
Coefficient of variation (2024)	**16,1%**	
CONSUMPTION		
Annual consumption (DDD)	**19.192.701**	
Consumption of DDD (per 100.000 insured persons)	**164.645**	
Average annual consumption per insured consumer (in DDD)	**233**	
Percentage insured consumers with more than 3 times the average consumption	**9,14%**	
Coefficient of variation[2] (2014-2016)	**17,67%**	**NS**
Coefficient of variation[3] (2022-2024)	**16,45%**	
Trend[3] (2014-2024)	**0,06%**	**NS**
Trend[4] (2014-2022)	**0,15%**	*******
Trend[5] (2022-2024)	**-0,30%**	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	**22.681.141€**	
Average annual expenditure per insured	**1,95€**	
Average patient share per insured consumer	**16,8%**	
Percentage low-cost medication	**88,3%**	
Trend (2014-2024)	**-3,29%**	
Trend (2022-2024)	**1,39%**	

Link to the report: RAPPORT-EN-Agents_Dopaminergiques_Antiparkinsoniens_2024.pdf

Gabapentinoids

Main prescribers: *General practitioners*	72%	
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]	5,5%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	1,85%	
Median age	64 y.	
Percentage of women	60,4%	
Ratio Preferential rate/General rate	2,41	
Coefficient of variation (2024)	18,0%	
CONSUMPTION		
Annual consumption (DDD)	29.725.254	
Consumption of DDD (per 100.000 insured persons)	254.999	
Average annual consumption per insured consumer (in DDD)	138	
Percentage insured consumers with more than 3 times the average consumption	6,81%	
Coefficient of variation [2] (2014-2016)	19,54%	NS
Coefficient of variation [3] (2022-2024)	16,83%	
Trend [3] (2014-2024)	8,96%	***
Trend [4] (2014-2022)	10,86%	***
Trend [5] (2022-2024)	1,71%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	19.113.404€	
Average annual expenditure per insured	1,64€	
Average patient share per insured consumer	18,6%	
Percentage low-cost medication	100,0%	
Trend (2014-2024)	-2,00%	
Trend (2022-2024)	3,90%	

Link to the report: RAPPORT-EN-Gabapentinoides_2024.pdf

Methylphenidate

Main prescribers: *Psychiatry*	45%	
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]	NA	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	2,22%	
Median age	13 y.	
Percentage of women	27,0%	
Ratio Preferential rate/General rate	0,74	
Coefficient of variation (2024)	54,5%	
CONSUMPTION		
Annual consumption (DDD)	5.948.629	
Consumption of DDD (per 100.000 insured persons)	372.530	
Average annual consumption per insured consumer (in DDD)	168	
Percentage insured consumers with more than 3 times the average consumption	3,55%	
Coefficient of variation[2] (2014-2016)	60,92%	NS
Coefficient of variation[3] (2022-2024)	63,4%	
Trend[3] (2014-2024)	2,42%	***
Trend[4] (2014-2022)	2,47%	*
Trend[5] (2022-2024)	2,23%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	5.470.980€	
Average annual expenditure per insured	3,43€	
Average patient share per insured consumer	19,7%	
Percentage low-cost medication	NA	
Trend (2014-2024)	0,01%	
Trend (2022-2024)	4,99%	

Link to the report: RAPPORT-EN-Methylphenidate_6-17_2024.pdf

Opioids

Main prescribers: *General practitioners*	80%	
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]	15,6%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	9,72%	
Median age	59 y.	
Percentage of women	57,5%	
Ratio Preferential rate/General rate	1,68	
Coefficient of variation (2024)	17,0%	
CONSUMPTION		
Annual consumption (DDD)	64.016.555	
Consumption of DDD (per 100.000 insured persons)	549.168	
Average annual consumption per insured consumer (in DDD)	57	
Percentage insured consumers with more than 3 times the average consumption	8,63%	
Coefficient of variation[2] (2014-2016)	19,87%	NS
Coefficient of variation[3] (2022-2024)	15,36%	
Trend[3] (2014-2024)	-1,21%	**
Trend[4] (2014-2022)	-0,80%	***
Trend[5] (2022-2024)	-2,86%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	56.477.400€	
Average annual expenditure per insured	4,84€	
Average patient share per insured consumer	21,0%	
Percentage low-cost medication	96,3%	
Trend (2014-2024)	-1,78%	
Trend (2022-2024)	-0,07%	

Link to the report: RAPPORT-EN-Opiaces_2024.pdf

Antimigraine preparation

Main prescribers: *Neurology*	59%	
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]	42,6%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	0,38%	
Median age	45 y.	
Percentage of women	82,3%	
Ratio Preferential rate/General rate	1,1	
Coefficient of variation (2024)	27,6%	
CONSUMPTION		
Annual consumption (DDD)	7.379.969	
Consumption of DDD (per 100.000 insured persons)	63.309	
Average annual consumption per insured consumer (in DDD)	169	
Percentage insured consumers with more than 3 times the average consumption	8,58%	
Coefficient of variation[2] (2014-2016)	27,67%	NS
Coefficient of variation[3] (2022-2024)	31,01%	
Trend[3] (2014-2024)	28,10%	***
Trend[4] (2014-2022)	31,44%	NS
Trend[5] (2022-2024)	15,54%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	56.191.514€	
Average annual expenditure per insured	4,82€	
Average patient share per insured consumer	3,3%	
Percentage low-cost medication	36,9%	
Trend (2014-2024)	43,23%	
Trend (2022-2024)	22,35%	

Link to the report: RAPPORT-EN-Antimigraineux_2024.pdf

9. RESPIRATORY SYSTEM

Antihistamines for systemic use

Main prescribers: *General practitioners*	82%	
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]	32,9%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	4,31%	
Median age	51 y.	
Percentage of women	60,4%	
Ratio Preferential rate/General rate	1,13	
Coefficient of variation (2024)	31,8%	
CONSUMPTION		
Annual consumption (DDD)	61.322.155	
Consumption of DDD (per 100.000 insured persons)	526.054	
Average annual consumption per insured consumer (in DDD)	122	
Percentage insured consumers with more than 3 times the average consumption	8,02%	
Coefficient of variation[2] (2014-2016)	13,57%	NS
Coefficient of variation[3] (2022-2024)	18,07%	
Trend[3] (2014-2024)	-0,98%	**
Trend[4] (2014-2022)	-0,99%	NS
Trend[5] (2022-2024)	-0,92%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	5.842.993€	
Average annual expenditure per insured	0,5€	
Average patient share per insured consumer	45,6%	
Percentage low-cost medication	100,0%	
Trend (2014-2024)	-2,43%	
Trend (2022-2024)	3,56%	

Link to the report: RAPPORT-EN-Antihistaminiques_A_Usage_Systemique_2024.pdf

Drugs for obstructive airway diseases

Main prescribers: *General practitioners*	73%	
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]	2,6%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	15,84%	
Median age	49 y.	
Percentage of women	53,9%	
Ratio Preferential rate/General rate	1,18	
Coefficient of variation (2024)	20,1%	
CONSUMPTION		
Annual consumption (DDD)	240.433.266	
Consumption of DDD (per 100.000 insured persons)	2.062.566	
Average annual consumption per insured consumer (in DDD)	130	
Percentage insured consumers with more than 3 times the average consumption	8,02%	
Coefficient of variation[2] (2014-2016)	10,98%	NS
Coefficient of variation[3] (2022-2024)	13,95%	
Trend[3] (2014-2024)	0,21%	NS
Trend[4] (2014-2022)	-0,02%	***
Trend[5] (2022-2024)	1,13%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	288.891.348€	
Average annual expenditure per insured	24,78€	
Average patient share per insured consumer	11,1%	
Percentage low-cost medication	42,4%	
Trend (2014-2024)	3,95%	
Trend (2022-2024)	9,28%	

Link to the report: RAPPORT-EN-Medic_Affections_Respiratoires_Obstructives_2024.pdf

10. SENSORY ORGANS

Antiglaucoma preparations and miotics

Main prescribers: *Ophthalmological surgery*	79%	
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]	5,0%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	2,21%	
Median age	72 y.	
Percentage of women	53,6%	
Ratio Preferential rate/General rate	0,97	
Coefficient of variation (2024)	13,9%	
CONSUMPTION		
Annual consumption (DDD)	106.970.818	
Consumption of DDD (per 100.000 insured persons)	917.653	
Average annual consumption per insured consumer (in DDD)	415	
Percentage insured consumers with more than 3 times the average consumption	4,68%	
Coefficient of variation[2] (2014-2016)	15,31%	NS
Coefficient of variation[3] (2022-2024)	14,55%	
Trend[3] (2014-2024)	4,39%	***
Trend[4] (2014-2022)	4,75%	***
Trend[5] (2022-2024)	2,99%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	21.465.563€	
Average annual expenditure per insured	1,84€	
Average patient share per insured consumer	21,6%	
Percentage low-cost medication	86,9%	
Trend (2014-2024)	-1,20%	
Trend (2022-2024)	3,19%	

Link to the report: RAPPORT-EN-Myotiques_Et_Preparations_Contre_Le_Glaucome_2024.pdf

11. IMMUNITY

Vaccination against influenza (65+/excl. nursing homes)

Main prescribers: *Pseudo-prescriptions*	79%	
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]	0,0%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	50,79%	
Median age	76 y.	
Percentage of women	55,2%	
Ratio Preferential rate/General rate	0,87	
Coefficient of variation (2024)	11,8%	
CONSUMPTION		
Annual consumption (DDD)	1.308.270	
Consumption of DDD (per 100.000 insured persons)	52.967	
Average annual consumption per insured consumer (in DDD)	1	
Percentage insured consumers with more than 3 times the average consumption	0,00%	
Coefficient of variation[2] (2014-2016)	7,73%	NS
Coefficient of variation[3] (2022-2024)	10,61%	
Trend[3] (2014-2024)	-0,13%	*
Trend[4] (2014-2022)	0,17%	***
Trend[5] (2022-2024)	-1,33%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	18.183.678€	
Average annual expenditure per insured	7,36€	
Average patient share per insured consumer	21,3%	
Percentage low-cost medication	NA	
Trend (2014-2024)	6,93%	
Trend (2022-2024)	1,87%	

Link to the report: RAPPORT-EN-Vaccination_Contre_La_Grippe_Hors_Mrs-mrpa_65_Et_Plus_2024.pdf

12. CROSS-SYSTEM ANALYSES

Polypharmacy (65 years and older)

Main prescribers: *General practitioners*	78%	
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]	36,6%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	44,14%	
Median age	76 y.	
Percentage of women	54,6%	
Ratio Preferential rate/General rate	1,3	
Coefficient of variation (2024)	7,4%	
CONSUMPTION		
Annual consumption (DDD)	2.239.975.160	
Consumption of DDD (per 100.000 insured persons)	90.687.621	
Average annual consumption per insured consumer (in DDD)	2.055	
Percentage insured consumers with more than 3 times the average consumption	0,39%	
Coefficient of variation[2] (2021-2023)	8,98%	NS
Coefficient of variation[3] (2022-2024)	8,82%	
Trend[3] (2021-2024)	1,22%	***
Trend[4] (2021-2022)	0,16%	**
Trend[5] (2022-2024)	1,76%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	1.104.272.239 €	
Average annual expenditure per insured	447,08€	
Average patient share per insured consumer	11,0%	
Percentage low-cost medication	70,3%	
Trend (2021-2024)	7,54%	
Trend (2022-2024)	8,90%	

Link to the report: RAPPORT-EN-Polymedication_65_Et_Plus_Min_80_Ddd_2024.pdf

Anticholinergics (65 years and older)

Main prescribers: *General practitioners*	85%	
CONTEXT		
Percentage of sales not covered by the health insurance (NIHDI) [1]	37,5%	
PROFILE OF INSURED CONSUMERS		
Percentage of insured consumers	17,58%	
Median age	75 y.	
Percentage of women	65,5%	
Ratio Preferential rate/General rate	1,55	
Coefficient of variation (2024)	12,0%	
CONSUMPTION		
Annual consumption (DDD)	137.425.499	
Consumption of DDD (per 100.000 insured persons)	5.563.808	
Average annual consumption per insured consumer (in DDD)	316	
Percentage insured consumers with more than 3 times the average consumption	2,85%	
Coefficient of variation[2] (2021-2023)	13,05%	NS
Coefficient of variation[3] (2022-2024)	12,89%	
Trend[3] (2021-2024)	-0,32%	NS
Trend[4] (2021-2022)	-0,86%	NS
Trend[5] (2022-2024)	-0,05%	
DIRECT EXPENDITURE (based on DDD)		
Annual expenditure borne by the insurance	43.802.330€	
Average annual expenditure per insured	17,73€	
Average patient share per insured consumer	20,7%	
Percentage low-cost medication	86,5%	
Trend (2021-2024)	-0,05%	
Trend (2022-2024)	0,78%	

Link to the report: RAPPORT-EN-Anticholinergiques_65_Et_Plus_Min_80_Ddd_2024.pdf

13. FOOTNOTES

1 Approximate value estimated from the discrepancy between the sales declarations of wholesalers to pharmacies converted into DDD and what is paid by the health insurance and the patients' share (see Annex D). This is a contextual indicator.

2 The test compares the coefficients of variation for the two periods and indicates whether the difference is statistically significant.

3 The test indicates whether the observed slope is statistically significantly different from 0%.

4 The test indicates whether the break in trend between the two periods is statistically significant.